# Simvastatin to Prevent SCI-Induced Bone Loss

> **NCT02946424** · PHASE2 · UNKNOWN · sponsor: **Craig Hospital** · enrollment: 76 (estimated)

## Conditions studied

- Spinal Cord Injuries
- Osteoporosis

## Interventions

- **DRUG:** Placebo Oral Capsule
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT02946424
- **Lead sponsor:** Craig Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2023-09
- **Final completion:** 2023-09-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02946424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02946424, "Simvastatin to Prevent SCI-Induced Bone Loss". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02946424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*